Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
A research study to determine the safety, efficacy, and tolerability of Therasphere® (also known as Y-90, or Y-90 Therasphere) combined with or without sorafenib (Nexavar®), in patients with hepatocellular carcinoma (HCC, or liver cancer), awaiting liver transplantation.
Epistemonikos ID: 5bc3f6c6ec5980c71815144ef9da27a885eedc93
First added on: May 05, 2024